Showing 5061-5070 of 5771 results for "".
- Oculus Introduces Pentacam AXL Wavehttps://modernod.com/news/oculus-introduces-pentacam-axl-wave/2479548/Oculus has announced that it plans to introduce its next-generation Pentacam—the Pentacam AXL Wave. The new Pentacam AXL Wave is the first device to combine Scheimpflug tomography with axial length, total eye wavefront, objective refraction, and retroillumination, according to Oculus. New
- FDA Approves Eylea Injection Prefilled Syringehttps://modernod.com/news/fda-approves-eylea-injection-prefilled-syringe/2476803/Regeneron Pharmaceuticals announced that the FDA has approved Eylea (aflibercept) Injection prefilled syringe. The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials. The approval was made
- Lineage Cell Therapeutics Launches New Corporate Brandhttps://modernod.com/news/lineage-cell-therapeutics-launches-new-corporate-brand/2479549/Lineage Cell Therapeutics, previously BioTime, announced the effective change of its corporate name and formal launch of its new corporate brand. In connection with the launch, the company’s NYSE American ticker symbol has changed to “LCTX” and will be effective at the open of t
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop
- FDA Does Not Approve Kala Pharmaceuticals’ NDA for Dry Eye Disease Candidatehttps://modernod.com/news/fda-does-not-approve-kala-pharmaceuticals-nda-for-dry-eye-disease-candidate/2476799/Kala Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding the company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The FDA indicated that efficacy data from an additional clinica
- Ash Attia Becomes News CEO of Bionic Vision Technologieshttps://modernod.com/news/ash-attia-becomes-news-ceo-of-bionic-vision-technologies/2476797/Bionic Vision Technologies (BVT) has announced that Ash Attia has been named Chief Executive Officer (CEO), effective July 22. This appointment rounds comes shortly after the appointment of Brian Gordon as Chie
- Optronics Introduces Microcast Pro Medical Grade Microscope Video Camera Platformhttps://modernod.com/news/optronics-introduces-microcast-pro-medical-grade-microscope-video-camera-platform/2476796/Optronics announced the introduction of the next generation Microcast, the Microcast 4K PRO 3CMOS 2160p Ultra High Definition, and Microcast HD PRO 3CMOS 1080p high definition microscope video cameras for surgical and other technical microscope imaging applications including pathology, research,
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- National Center for Children’s Vision and Eye Health at Prevent Blindness Receives Renewed Granthttps://modernod.com/news/national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-receives-renewed-grant/2476794/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH), celebrating its 10-year anniversary, has announced that a second year of funding was received from the federal Health Resources and Services Administration’s Maternal and Child Health Bureau for $300,000 to su
- Sight Sciences Hires Several Industry Executives to Drive Growthhttps://modernod.com/news/sight-sciences-hires-several-industry-executives-to-drive-growth/2476793/Sight Sciences announced that Jessica Holmes, Brian Regan, and Jim Sluck have joined the company as Vice President of Health Policy & Reimbursement, Vice President of Strategy & Professional Relations, and Vice President of Dry